Rigel Pharmaceuticals Inc

Rigel Pharmaceuticals Inc

Health CarePharmaceuticals & Biotechnology
  • Price (USD)1.90
  • Today's Change-0.02 / -1.04%
  • Shares traded1.30m
  • 1 Year change-25.78%
  • Beta1.2675
Data delayed at least 15 minutes, as of Jul 07 2020 21:00 BST.
More ▼

Profile data is unavailable for this security.

About the company

Rigel Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in discovering, developing and providing novel small molecule drugs that improve the lives of patients with immune and hematological disorders, cancer and rare diseases. The Company’s research focuses on signaling pathways that are critical to disease mechanisms. The Company’s product include TAVALISSE is an oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase I study for its interleukin receptor associated kinase (IRAK) program. In addition, it has product candidates in development with partners BerGenBio AS, Daiichi Sankyo and Aclaris Therapeutics.

  • Revenue in USD (TTM)102.43m
  • Net income in USD-28.05m
  • Incorporated1996
  • Employees163.00
  • Location
    Rigel Pharmaceuticals Inc1180 Veterans BlvdSOUTH SAN FRANCISCO 94080-1985United StatesUSA
  • Phone+1 (650) 624-1100
  • Fax+1 (650) 624-1101
  • Websitehttps://www.rigel.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Spero Therapeutics Inc12.13m-79.11m282.36m57.00--3.38--23.28-4.19-4.190.64744.050.1034--8.95212,807.00-67.46---77.25-------652.19------0.00--357.56---46.24------
Pfenex Inc40.65m-5.43m283.25m85.00--3.40--6.97-0.1878-0.18781.232.430.4929--7.97501,802.50-6.59-18.37-7.39-21.9989.9483.19-13.36-53.10----0.00--238.7436.44102.67--35.47--
Bicycle Therapeutics PLC (ADR)8.55m-35.43m284.25m72.00--3.46--33.26-1.97-1.970.47634.540.0825--13.54118,694.40-34.22---38.83-------414.57------0.00--93.40---40.11------
Abeona Therapeutics Inc0.00-105.89m284.57m88.00--2.15-----1.66-1.660.001.580.00----0.00-62.08-29.61-74.80-32.36-------3,412.06----0.00---100.00---34.61------
Sutro Biopharma Inc41.26m-61.09m287.51m177.00--2.38--6.97-2.65-2.651.793.530.2316--6.65245,589.30-34.29---41.67-------148.06-----85.410.2274--11.24---57.84------
Menlo Therapeutics Inc1.75m-95.06m289.99m180.00--1.53--165.71-3.23-3.230.06111.130.0122----43,750.00-66.29---86.59--84.51---5,432.17--1.68--0.3206---100.00---43.27------
Concert Pharmaceuticals Inc79.00k-76.82m296.24m70.00--1.92--3,749.83-3.07-3.070.00315.210.0004--13.171,128.57-41.45-8.54-44.09-9.08-----97,236.71-29.27----0.00---89.75-33.96-39.52---3.15--
Liquidia Technologies Inc8.07m-48.61m297.04m64.00--10.25--36.80-2.26-2.260.37420.76750.1276----126,126.90-76.85---97.77--90.00---602.17-----57.970.4309--198.20--10.45------
Urovant Sciences Ltd0.00-146.75m310.15m70.00---------4.82-4.820.00-1.890.00----0.00-179.60---243.22-------------38.742.59-------31.79------
Cellular Biomedicine Group Inc290.66k-52.19m318.41m217.00--7.04--1,095.46-2.71-2.710.01512.330.0028--1.121,339.45-50.37-49.83-61.77-54.5681.3223.14-17,957.33-4,413.84----0.2367--51.48-9.64-28.34--104.77--
Rigel Pharmaceuticals, Inc.102.43m-28.05m320.28m163.00--4.08--3.13-0.1684-0.16840.61060.46570.6480.693313.41628,374.30-17.75-54.29-21.68-69.9599.07---27.39-213.283.68--0.1113--33.2048.365.09--28.64--
PDL BioPharma Inc54.06m-93.50m334.50m75.00--0.6223--6.19-0.7845-0.90350.45734.620.06834.043.20720,746.70-11.876.98-12.557.772.55---173.9026.1712.95--0.023531.21-72.36-37.65-2.25---50.29--
Aspira Women's Health Inc4.96m-15.23m343.26m52.00--64.68--69.27-0.1688-0.16880.05390.05450.532642.846.0295,288.46-163.67-106.43-269.84-139.7230.397.24-307.31-458.362.49--0.19--48.6412.48-34.00---12.41--
Wave Life Sciences Ltd17.12m-196.93m344.46m301.00--15.99--20.12-5.74-5.740.49870.83040.0512--3.4256,870.43-58.86-54.34-94.13-71.05-----1,150.43-1,455.31----0.00--10.89---32.04--46.03--
Emisphere Technologies, Inc.1.04m-2.15m349.29m12.00------334.57-0.0476-0.04760.0166-2.550.11622.183.90---23.92-287.20-----43.20-48.94-205.75-6,143.770.7765------190.75--75.13------
Data as of Jul 07 2020. Currency figures normalised to Rigel Pharmaceuticals Inc's reporting currency: US Dollar USD

Institutional shareholders

54.30%Per cent of shares held by top holders
HolderShares% Held
Fidelity Management & Research Co. LLCas of 31 Mar 202022.05m13.08%
Wellington Management Co. LLPas of 31 Mar 202015.71m9.32%
BlackRock Fund Advisorsas of 31 Mar 202013.06m7.75%
The Vanguard Group, Inc.as of 31 Mar 20208.35m4.96%
Millennium Management LLCas of 31 Mar 20208.16m4.84%
Tamarack Advisers LPas of 31 Mar 20205.55m3.29%
Rock Springs Capital Management LPas of 31 Mar 20205.50m3.26%
Invesco Advisers, Inc.as of 31 Mar 20205.00m2.97%
Renaissance Technologies LLCas of 31 Mar 20204.21m2.50%
T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 20203.94m2.34%
More ▼
Data from 31 Mar 2020 - 31 Mar 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.